-
Product Insights
Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial – Drugs In Development, 2023
Global Markets Direct’s Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial provides in depth analysis on Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
FKBP Type Peptidyl-Prolyl Cis-Trans Isomerase – Drugs In Development, 2023
Global Markets Direct’s FKBP Type Peptidyl-Prolyl Cis-Trans Isomerase provides in depth analysis on FKBP Type Peptidyl-Prolyl Cis-Trans Isomerase targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in FKBP...
-
Product Insights
NewLikelihood of Approval Analysis for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Overview How likely is it that the drugs in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Non Muscle Invasive Bladder Cancer...
-
Product Insights
Interporto Campano and CIS – Solar Plant
Interporto Campano and CIS - Solar Plant is a solar PV project located in Campania, Italy. The project is owned and developed by Enel SpA. The project is currently active. Empower your strategies with our Interporto Campano and CIS - Solar Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BPC-1 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BPC-1 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BPC-1 in Metastatic Breast Cancer Drug Details: BPC-1 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Isuzinaxib in Acute Renal Failure (ARF) (Acute Kidney Injury)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Isuzinaxib in Acute Renal Failure (ARF) (Acute Kidney Injury) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Isuzinaxib in Acute Renal Failure (ARF)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dinutuximab in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dinutuximab in Osteosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dinutuximab in Osteosarcoma Drug Details: Dinutuximab (Unituxin) is a chimeric monoclonal antibody, composed...
-
Track & Monitor
Innovation in automotive: CI engine controls
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the automotive industry’s CI engine controls segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Dedifferentiated Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Dedifferentiated Liposarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Dedifferentiated Liposarcoma Drug Details: Pembrolizumab (Keytruda) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Pleomorphic Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Pleomorphic Liposarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Pleomorphic Liposarcoma Drug Details: Pembrolizumab (Keytruda) is an antineoplastic...